Sno	REC Reference	IRAS	Name of Trial	Target Number of Patients Agreed?	Minimum Number of Patients Agreed	Maximum Number of Patients Agreed	Target Date To Recruit Patients Agreed?	Date Agreed to Recruit Target Number of Patients	Total Number of Patients Recruited at the Agreed Target Date	Date That The Trial Closed to Recruitment	Total Number Of Study Participants Recruited	Reason for Closure of Trial
1	14/ES/0001	141631	Randomised, Double-Blind, Placebo-Controlled, Parallel-Group Study to Assess Cardiovascular Outcomes Following Treatment with Ertugliflozin (MK-8835/PF-04971729) in Participants with Type 2 Diabetes Mellitus and Established Vascular Disease	Number Agreed	10	10	Not Available / Not agreed		0	29/11/2019	3	Recruitment Finished
2	14/WM/0049	145163	An openlabel singlearm multicentre noncontrolled phase 3a trial investigating safety and efficacy of nonacog betapegol (N9GP) in prophylaxis and treatment of bleeding episodes in previously untreated patients with haemophilia B (FIX activity ≤2%)	Range Agreed	1	1	Date Agreed	30/09/2019	0	02/03/2020	0	Withdrawn By Host
3	15/LO/0605	161395	Phase I open label, dose escalation trial to determine the MTD, safety, PK and efficacy of afatinib monotherapy inchildren aged 2 years to <18 years with recurrent/refractory neuroectodermal tumours, rhabdomyosarcoma and/orother solid tumours with known ErbB pathway deregulation regardless of tumour histology.	Range Agreed	2	6	Date Agreed	31/12/2019	7	01/06/2020	7	Withdrawn By Sponsor
4	15/LO/1419	183975	A randomized, phase 3 trial with anti-PD-1 monoclonal antibody pembrolizumab (MK-3475) versus placebo for patients with early stage NSCLC after resection and completion of standard adjuvant therapy (PEARLS)	Range Agreed	5	8	Date Agreed	15/11/2019	11	15/11/2019	11	Recruitment Finished
5	16/LO/0086	193561	A Single-Masked, Randomised, Controlled, Parallel Group, Phase 3 Clinical Trial Of Retinal Gene Therapy For Choroideremia Using An Adeno-Associated Viral Vector (AAV2) Encoding Rab Escort Protein 1 (REP1)	Range Agreed	1	10	Date Agreed	30/09/2019	3	02/10/2019	3	Recruitment Finished

6	16/LO/2126	218039	A randomized trial comparing the ELUVIA™ drug-eluting stent versus bare metal self-expanding nitinol stents in the treatment of superficial femoral and/or proximal popliteal arteries.	Range Agreed	1	10	Date Agreed	31/01/2020	1	31/03/2020	1	Recruitment Finished
7	16/NW/0082	184887	Breast reconstruction Outcomes With and without StratticE	Range Agreed	100	200	Date Agreed	31/10/2019	121	31/10/2019	121	Recruitment Finished
8	16/SC/0551	214620	XIRIUS Study (A Dose Escalation, Phase 1/2 Clinical Trial of Retinal Gene Therapy for X-linked Retinitis Pigmentosa Using an Adeno-Associated Viral Vector (AAV8) Encoding Retinitis Pigmentosa GTPase Regulator (RPGR))	Range Agreed	1	15	Date Agreed	28/02/2020	7	20/03/2020	7	Withdrawn By Sponsor
9	16/WM/0396	210511	A phase 3 randomized, open-label (sponsor-blind), activecontrolled, parallel-group, multi-center, event driven study in non-dialysis subjects with anemia associated with chronic kidney disease to evaluate the safety and efficacy of daprodustat compared to darbepoetin alfa	Range Agreed	2	10	Date Agreed	31/12/2020	1	25/09/2020	1	Recruitment Finished
10	17/EE/0017	213606	Zambon - Promis - A double-blind, placebo controlled, multicentre, clinical trial to investigate the efficacy and safety of 12 months of therapy with inhaled Promixin (colistimethate sodium) in the treatment of subjects with non-cystic fibrosis bronchiectasis chronically infected with Pseudomonas aeruginosa (P.aeruginosa)	Number Agreed	3	3	Date Agreed	29/02/2020	1	10/07/2020	1	Recruitment Finished
11	17/EM/0121	221773	A randomized, open, multinational, multicentre, 2-part study in spontaneously breathing preterm neonates with mild to moderate respiratory distress syndrome to investigate the safety, tolerability and efficacy of inhaled nebulised poractant alfa (porcine surfactant, curosurf®) in comparison with nCPAP alone	Range Agreed	1	6	Date Agreed	31/05/2022	5	23/04/2020	5	Withdrawn By Sponsor

12	17/EM/0122	224376	A Phase 3, Open-Label, Multicenter Study Of ALXN1210 In Children And Adolescents With Atypical Hemolytic-Uremic Syndrome (aHUS)	Range Agreed	1	1	Date Agreed	30/11/2020	0	23/01/2020	0	Recruitment Finished
13	17/EM/0152	216307	A Multi-center, Randomised, Double-blind, Placebo-controlled Phase III Trial of the FLT3 Inhibitor Gilteritinib Administered as Maintenance Therapy Following Allogeneic Transplant for Patients with FLT3/ITD AML	Range Agreed	1	3	Date Agreed	31/03/2020	5	15/02/2020	5	Recruitment Finished
14	17/LO/0182	213821	A Prospective, Randomized, Multicenter Controlled Trial of CERAMENTâ„¢|G as Part of Surgical Repair of Open Diaphyseal Tibial Fractures	Range Agreed	12	20	Date Agreed	30/12/2020	8	15/06/2020	8	Withdrawn By Sponsor
15	17/LO/0236	220765	PROMINENT PEMAFIBRATE TO REDUCE CARDIOVASCULAR OUTCOMES BY REDUCING TRIGLYCERIDES IN PATIENTS WITH DIABETES	Range Agreed	5	10	Date Agreed	31/03/2020	6	14/02/2020	6	Recruitment Finished
16	17/LO/0371	212841	Randomized, Assessor-Masked, Active-Controlled, Phase 3 Study to Evaluate Efficacy, Safety and Tolerability of 0.08% Polyhexamethylene Biguanide (PHMB) Ophthalmic Solution in Comparison with 0.02% PHMB + 0.1% Propamidine Combination Therapy in Subjects Affected by Acanthamoeba keratitis	Range Agreed	1	5	Date Agreed	31/12/2020	3	07/09/2020	3	Withdrawn By Sponsor
17	17/LO/0506	220370	A Single Arm, Open-Label, Multi-Centre, Phase I/II Study Evaluating the Safety and Clinical Activity of AUTO3, a CAR T Cell Treatment Targeting CD19 and CD22 in Paediatric and Young Adult Patients with Relapsed Refractory B-cell Acute Lymphoblastic Leukaemia	Range Agreed	10	15	Date Agreed	31/12/2019	11	18/05/2020	11	Withdrawn By Sponsor
18	17/LO/1088	228921	A Phase 3, 2-Arm, Open-label Study to Evaluate the Safety and Pharmacodynamics of Long-termIvacaftor Treatment in Subjects With Cystic Fibrosis Who Are Less Than 24 Months of Age at Treatment Initiation and Have a CFTR Gating Mutation	Range Agreed	1	3	Date Agreed	11/12/2019	0	11/12/2019	0	Recruitment Finished

19	17/LO/1306	228268	A phase III randomized open-label multi-center study of ruxolitinib vs. best available therapy in patients with corticosteroid-refractory chronic graft vs host disease after allogenic stem cell transplantation (REACH 3)	Range Agreed	1	3	Date Agreed	11/10/2019	4	06/12/2019	4	Recruitment Finished
20	17/NS/0106	230907	The hydrus microstent for refractory open-angle glaucoma: A prospective, multicenter clinical trial	Range Agreed	3	10	Date Agreed	31/05/2019	3	23/10/2019	3	Recruitment Finished
21	17/SC/0245	219967	A Prospective, Open-label, Long-term Safety and Efficacy Study of Teduglutide in Pediatric Patients with Short Bowel Syndrome Who Completed TED-C14-006 or SHP633-301	Range Agreed	1	1	Not Available / Not agreed		0	30/06/2020	2	Recruitment Finished
22	17/SC/0554	225522	A Phase III, multicenter, randomized controlled study to compare safety and efficacy of a haploidentical HSCT and adjunctive treatment with ATIR101, a T-lymphocyte enriched leukocyte preparation depleted ex vivo of host alloreactive T-cells, versus a haploidentical HSCT with post-transplant cyclophosphamide in patients with a hematologic malignancy (HATCY study)	Number Agreed	4	4	Date Agreed	30/12/2020	4	12/11/2019	4	Withdrawn By Sponsor
23	17/WM/0308	226910	Randomized, Double-Blind, Phase 3B Trial to Evaluate the Safety and Efficacy of 2 Treatment Regimens of Aztreonam 75 mg Powder and Solvent for Nebulizer Solution / Aztreonam for Inhalation Solution (AZLI) in Pediatric Subjects with Cystic Fibrosis (CF) and New Onset Respiratory Tract Pseudomonas aeruginosa (PA) Infection/Colonization	Range Agreed	1	2	Date Agreed	01/11/2019	2	17/02/2020	2	Recruitment Finished
24	17/WM/0316	226628	A Post-Approval Registry of the TREO® Stent-Graft for Patients with Infrarenal Abdominal Aortic Aneurysms	Range Agreed	1	10	Date Agreed	01/06/2020	4	31/12/2019	4	Recruitment Finished

25	18/EE/0236	242210	Efficacy and safety of Fixed-Dose Combination (FDC) products containing trazodone andgabapentin in patients affected by painful diabetic neuropathy: randomized, controlled, dosefinding study	Range Agreed	1	8	Date Agreed	30/03/2020	1	14/04/2020	1	Recruitment Finished
26	18/EM/0153	240773	A PHASE 3, RANDOMIZED, DOUBLE-BLIND,PLACEBO-CONTROLLED STUDY TO EVALUATE THEEFFICACY AND SAFETY OF AG-348 IN NOTREGULARLY TRANSFUSED ADULT SUBJECTS WITHPYRUVATE KINASE DEFICIENCY	Range Agreed	1	2	Date Agreed	28/02/2020	0	05/02/2020	0	Recruitment Finished
27	18/EM/0166	246673	PULMOCIDE - A double-blind, placebo-controlled study to assess the effects of inhaled PC945 in the treatment of culture-positive Aspergillus fumigatus infection in subjects with moderate to severe asthma	Range Agreed	2	3	Date Agreed	31/12/2019	1	01/06/2020	1	Withdrawn By Sponsor
28	18/ES/0124	248009	An open-label- study to assess the safety, pharmacokinetics and pharmacodynamics of inhaled PC945 in adult Cystic Fibrosis (CF) patients with persistent pulmonary Aspergillus fumigatus infection.	Range Agreed	1	9	Date Agreed	31/12/2019	4	01/06/2020	4	Withdrawn By Sponsor
29	18/LO/0755	245151	A Randomized, Open-label, 24-Week Safety, Efficacy, and Pharmacokinetic Study of Teduglutide in Infants 4 to 12 Months of Age with Short Bowel Syndrome Who are Dependent on Parenteral Support	Range Agreed	1	2	Date Agreed	30/11/2019	1	02/03/2020	2	Recruitment Finished
30	18/LO/1370	249657	PREcision Event Monitoring of PatienTs with Heart Failure usingHeartLogicTM	Number Agreed	10	10	Date Agreed	30/12/2023	18	26/06/2020	18	Recruitment Finished
31	18/LO/1922	251251	A Phase 2a, Open-label, Single and Multiple Dose Study to Evaluate the Pharmacokinetics, Safety, Tolerability and Treatment Effect of GBT440 in Pediatric Participants with Sickle Cell Disease	Range Agreed	1	3	Date Agreed	31/05/2021	2	06/01/2020	2	Withdrawn By Sponsor
32	18/LO/2112	242027	BIOSOLVE-IV - BIOTRONIKS - Safety and Performance in de Novo Lesion of Native Coronary Arteries with Magmaris- Registry: BIOSOLVE-IV	Range Agreed	5	10	Date Agreed	28/09/2020	9	14/07/2020	9	Recruitment Finished

33	18/LO/2136	251414	A randomized, multicentre, double-blind, placebo-controlled, phase-III clinical study to evaluate the efficacy and safety of intrathecally administered RO7234292 (RG6042) in patients with manifest Huntington's Disease.	Range Agreed	1	8	Date Agreed	30/06/2020	11	17/04/2020	11	Recruitment Finished
34	18/NE/0142	242919	A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Multicenter Study to Evaluate the Efficacy and Safety of Obeticholic Acid in Subjects with Compensated Cirrhosis due to Nonalcoholic Steatohepatitis Protocol 747-304	Range Agreed	1	8	Date Agreed	08/11/2019	1	22/11/2019	1	Recruitment Finished
35	18/NE/0169	243977	A 6-month randomised, double-blind, placebo controlled multicentre parallel group study to evaluate efficacy and safety of bumetanide 0.5mg twice a day followed by an open label active 6-month treatment period with bumetanide (0.5mg twice a day) and a 6 weeks discontinuation period after treatment stop	Range Agreed	6	12	Date Agreed	31/03/2020	11	21/02/2020	11	Recruitment Finished
36	18/NI/0178	253727	A Phase 1 / 2, Drug-Drug Interaction Study of FDL169 and FDL176 in Healthy Subjects and in Cystic Fibrosis Subjects Homozygous for the F508del-CFTR mutation	Range Agreed	1	4	Date Agreed	29/02/2020	0	10/12/2019	0	Withdrawn By Sponsor
37	18/NW/0325	244842	A Randomized, Double-Blind, Placebo-Controlled Study of the Safety and Efficacy of Varying Doses and Dose Regimens of Evinacumab in Patients with Persistent Hypercholesterolemia Despite Maximally Tolerated Lipid Modifying Therapy	Range Agreed	1	3	Date Agreed	31/12/2019	3	24/11/2019	3	Recruitment Finished
38	18/NW/0565	246158	A Phase II randomised , double blind, placebo-controlled, parallel group, multicentre study to evaluate the safety and efficacy of repeated oral doses of Blautix in adult subjects with irritable bowel syndrome (IBS) subtypes IBS-C and IBS-D	Range Agreed	6	14	Date Agreed	31/03/2020	4	17/01/2020	4	Withdrawn By Host

39	18/NW/0599	242748	Study of TRE Seals on Early Post-operative Subjects (STEPS)	Range Agreed	1	10	Date Agreed	29/07/2019	3	30/10/2019	4	Recruitment Finished
40	18/NW/0742	236247	A Phase 2, Randomized, Double-Blind, Placebo-Controlled Efficacy and Safety Study of Palovarotene in Subjects with Multiple Osteochondromas	Range Agreed	4	15	Date Agreed	30/06/2019	3	05/12/2019	7	Withdrawn By Host
41	18/SC/0395	245499	A Multicenter, Randomized, Phase III Registration Trial of Transplantation of NiCord®, Ex Vivo Expanded, Umbilical Cord Blood-derived, Stem and Progenitor Cells, versus Unmanipulated Umbilical Cord Blood for Patients with Hematological Malignancies	Range Agreed	1	3	Date Agreed	31/12/2019	1	24/12/2019	1	Recruitment Finished
42	18/SS/0140	252391	Epidemiological analysis for Hereditary Angioedema Disease (EHA Study)	Number Agreed	100	100	Date Agreed	30/06/2022	11	28/02/2020	11	Withdrawn By Sponsor
43	18/WM/0022	237623	AN OPEN-LABEL STUDY TO EVALUATE THEEFFICACY AND SAFETY OF AG-348 IN REGULARLYTRANSFUSED ADULT SUBJECTS WITH PYRUVATE KINASE (PK) DEFICIENCY	Range Agreed	1	2	Date Agreed	31/12/2019	1	31/12/2019	1	Recruitment Finished
44	18/WS/0199	253868	A Phase 2b, multicentre, randomized, double-blind, placebo-controlled, parallel-group study to evaluate the efficacy, safety, and tolerability of cenerimod in subjects with moderate to severe systemic lupus erythematosus (SLE)	Number Agreed	2	2	Date Agreed	15/08/2020	0	09/07/2020	0	Withdrawn By Host
45	18/YH/0055	241341	A Phase 2, Prospective, Randomized, Open-label Study on the Efficacy of Defibrotide Added to Standard of Care Immunoprophylaxis for the Prevention of Acute Graft-versus- Host-Disease in Adult and Pediatric Patients After Allogeneic Hematopoietic Stem Cell Transplant	Range Agreed	1	2	Date Agreed	31/12/2019	4	31/10/2019	4	Recruitment Finished
46	18/YH/0264	248535	A Two-Period, Open-label Trial Evaluating the Efficacy and Safety of Dasiglucagon for the Treatment of Children with Congenital Hyperinsulinism	Range Agreed	1	3	Date Agreed	31/01/2020	3	24/07/2020	3	Recruitment Finished

47	19/EE/0091	256412	An open-label, pilot study to assess safety, tolerability, pharmacokinetics and effects of inhaled PC945 in the pre-emptive treatment of Aspergillus fumigatus colonisation in lung transplant recipients	Range Agreed	1	4	Date Agreed	28/02/2020	0	01/06/2020	0	Withdrawn By Sponsor
48	19/EM/0015	248765	A randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of sarilumab in patients with polymyalgia rheumatica	Range Agreed	1	3	Date Agreed	31/07/2020	0	21/07/2020	0	Withdrawn By Sponsor
49	19/EM/0016	253279	VITALITY (GCA) A randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of sarilumab in patients with giant cell artheritis	Range Agreed	1	3	Date Agreed	31/07/2020	1	19/07/2020	1	Withdrawn By Sponsor
50	19/EM/0047	257111	A Phase III, Multicenter, Randomized, Double-Masked, Active Comparator-Controlled Study To Evaluate The Efficacy And Safety Of Faricimab In Patients With Neovascular Age-Related Macular Degeneration (TENAYA)	Number Agreed	4	4	Date Agreed	31/12/2019	3	24/10/2019	3	Recruitment Finished
51	19/EM/0094	259038	Effects of N-Acetyl-L-Leucine on Niemann-Pick disease type C: A multinational, multicenter, open-label, rater-blinded Phase II study.	Range Agreed	1	4	Date Agreed	31/01/2020	1	31/01/2020	1	Recruitment Finished
52	19/EM/0220	265213	A Phase III, randomized, multicenter, open-label, non-inferiority studyevaluating the efficacy, safety and tolerability of switching to dolutegravir/lamivudine fixed dose combination in HIV-1 infected adults who are virologically suppressed	Range Agreed	1	2	Date Agreed	31/05/2020	0	20/04/2020	0	Withdrawn By Sponsor
53	19/LO/0157	256597	A study to evaluate safety, reactogenicity and immunogenicity of GSK Biologicals' RSV investigational vaccine based on viral proteins encoded by chimpanzee-derived adenovector (ChAd155-RSV) (GSK3389245A) in infants	Number Agreed	2	2	Date Agreed	30/09/2019	1	20/10/2019	1	Recruitment Finished

54	19/LO/0351	256743	A Phase 3, Randomized, Double-Blind, Study Comparing Risankizumab to Placebo in Subjects with Active Psoriatic Arthritis (PsA) Who Have a History of Inadequate Response to or Intolerance to at Least One Disease Modifying Anti- Rheumatic Drug (DMARD) Therapy	Range Agreed	1	3	Date Agreed	30/06/2020	0	11/03/2020	0	Recruitment Finished
55	19/LO/0352	257478	A Phase 3, Randomized, Double-Blind Study Comparing Risankizumab to Placebo in Subjects with Active Psoriatic Arthritis Including Those Who Have a History of Inadequate Response or intolerance to Biologic Therapy(ies)	Range Agreed	1	3	Date Agreed	30/06/2020	0	28/11/2019	0	Withdrawn By Sponsor
56	19/LO/1317	268821	A Phase 3, Open-label Study Evaluating the Long-term Safety and Efficacy of VX-445 Combination Therapy in Subjects With Cystic Fibrosis Who Are Heterozygous for the F508del Mutation and a Gating or Residual Function Mutation (F/G and F/RF Genotypes)	Range Agreed	1	3	Date Agreed	30/09/2020	2	26/05/2020	2	Recruitment Finished
57	19/LO/1318	268820	A Phase 3, Randomized, Double-blind, Controlled Study Evaluating the Efficacy and Safety of VX-445 Combination Therapy in Subjects With Cystic Fibrosis Who Are Heterozygous for the F508del Mutation and a Gating or Residual Function Mutation (F/G and F/RF Genotypes)	Range Agreed	1	3	Date Agreed	31/07/2020	2	26/05/2020	2	Recruitment Finished
58	19/NE/0195	264648	Open-label, randomized, two–arm, controlled study to assess the efficacy, safety, and tolerability of intravitreal (IVT) aflibercept compared to laser photocoagulation in patients with retinopathy of prematurity (ROP)	Range Agreed	1	2	Date Agreed	15/07/2020	0	03/09/2020	0	Recruitment Finished
59	19/NW/0161	257243	A Randomized, Double-Blind, Multicenter, Placebo-Controlled, Phase 2 Study to Evaluate the Safety, Tolerability and Pharmacokinetics of Itraconazole Administered as a Dry Powder for Inhalation (PUR1900) in Adult Asthmatic Patients with Allergic Bronchopulmonary Aspergillosis	Range Agreed	1	4	Date Agreed	31/01/2020	2	15/07/2020	2	Withdrawn By Sponsor

60	19/NW/0181	260431	A Randomised, Double-blind, Placebo-Controlled, Crossover, Dose Escalation Study of BLU-5937 in Subjects with Unexplained or Refractory Chronic Cough (RELIEF)	Range Agreed	1	5	Date Agreed	31/01/2020	5	04/04/2020	6	Withdrawn By Sponsor
61	19/NW/0482	269475	A Phase 3b, Randomized, Double-blind, Controlled Study Evaluating the Efficacy and Safety of VX-445/Tezacaftor/Ivacaftor in Cystic Fibrosis Subjects, Homozygous for F508del	Range Agreed	1	5	Date Agreed	30/03/2020	5	19/12/2019	5	Withdrawn By Sponsor
62	19/NW/0540	269907	A Phase 3, Open-label Study Evaluating the Long-term Safety of VX-445 Combination Therapy in Subjects With Cystic Fibrosis	Range Agreed	1	3	Date Agreed	31/07/2020	4	29/05/2020	4	Recruitment Finished
63	19/NW/0716	273613	A Phase 3b Open-label Study Evaluating the Safety of Elexacaftor/Tezacaftor/Ivacaftor Combination Therapy in Cystic Fibrosis Subjects	Range Agreed	1	5	Date Agreed	31/07/2020	5	23/07/2020	5	Recruitment Finished
64	19/YH/0093	255567	ATLAS - A Randomized Open-label, Phase 1b Study of the Safety of Pirfenidone Solution for inhalation (AP01) in Patients with Idiopathic Pulmonary Fibrosis	Range Agreed	3	5	Date Agreed	16/03/2020	7	29/04/2020	7	Recruitment Finished
65	20/NE/0104	282007	A Phase 3 Randomized Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants with Severe COVID-19	Range Agreed	1	9	Date Agreed	31/05/2020	1	29/05/2020	1	Recruitment Finished
66	20/NE/0126	282417	Phase 3 randomised, double-blind, placebo-controlled multi-center study to assess the efficacy and safety of ruxolitinib in patients with COVID-19 associated cytokine storm (RUXCOVID)	Range Agreed	3	14	Date Agreed	31/05/2020	2	18/09/2020	4	Recruitment Finished
67	20/NW/0168	281317	A randomised double-blind placebo-controlled trial to determine the safety and efficacy of inhaled SNG001 (IFN-β1a for nebulisation) for the treatment of patients with confirmed SARS-CoV-2 infection	Range Agreed	8	20	Date Agreed	15/05/2021	8	11/05/2020	8	Recruitment Finished